Kalvista pill succeeds in late-stage study for rare swelling disorder [Yahoo! Finance]
Pharvaris N.V. - Ordinary Shares (PHVS)
Company Research
Source: Yahoo! Finance
first oral “on-demand” treatment for people with the rare swelling disorder hereditary angioedema. In a statement Tuesday, KalVista said the drug, sebetralstat, met the study's main and secondary goals, reducing the severity of swelling attacks significantly faster than did a placebo. Participants on sebetralstat first felt relief from symptoms a median of 1.6 hours after receiving a low dose and 1.8 hours after a high dose, within range of available, injectable medicines. KalVista also said, without offering specifics, that the drug had a safety profile “similar to placebo.” No serious treatment-related adverse events occurred, and no patients left the trial because of side effects. The company plans to file for U.S. approval in the first half of 2024 and later this year in Europe and Japan. Dive Insight: Though hereditary angioedema, or HAE, is a rare condition estimated to affect one in 50,000 people globally, the disease has become a crowded area of drug research. Multip
Show less
Read more
Impact Snapshot
Event Time:
PHVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHVS alerts
High impacting Pharvaris N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PHVS
News
- Pharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesGlobeNewswire
- Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Wedbush from $35.00 to $31.00. They now have an "outperform" rating on the stock.MarketBeat
- Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.MarketBeat
PHVS
Earnings
- 5/8/24 - Beat
PHVS
Sec Filings
- 5/8/24 - Form 6-K
- 4/23/24 - Form 144
- 4/15/24 - Form 144
- PHVS's page on the SEC website